Ingimarsson Oddur, MacCabe James H, Sigurdsson Engilbert
a Faculty of Medicine, School of Health Sciences , University of Reykjavik, Iceland.
b Mental Health Services , Landspitali University Hospital , 101 Reykjavik , Iceland.
Nord J Psychiatry. 2018 Oct;72(7):497-500. doi: 10.1080/08039488.2018.1517189. Epub 2018 Oct 22.
Purpose of the article: Clozapine is the only evidence based treatment for treatment-resistant schizophrenia. Constipation is a well known side effect of clozapine treatment. The aims of this study are to describe the prevalence of constipation and ileus during clozapine treatment of patients with schizophrenia in Iceland and to assess the concomitant use of medication that can cause constipation, and laxatives used to treat constipation.
We identified 188 patients treated with clozapine by searching the electronic health records of Landspitali, the National University Hospital, during the study period 1.1.1998 - 21.11.2014. Cases of constipation and ileus were identified using an electronic search with keywords related to ileus in the patients' electronic health records. Detailed medication use was available for 154 patients that used clozapine for at least one year.
Four out of 188 patients were diagnosed with ileus that resulted in admission to hospital. Two of these required a permanent stoma as a consequence of their ileus. Laxatives were prescribed for 24 out of 154 patients (15.4%) while on clozapine. In total 40.9% of the patients either had laxatives prescribed or had constipation documented in the medical records. Apart from clozapine, other medications known to cause constipation were prescribed to 28 out of 154 patients (18.2%).
Constipation is a common problem during clozapine treatment which can progress to full-blown ileus which can be fatal. Clinicians need to monitor signs of constipation during treatment with clozapine and respond to it with lifestyle advice and laxative treatment.
本文的目的:氯氮平是唯一经循证医学证实可用于治疗难治性精神分裂症的药物。便秘是氯氮平治疗中众所周知的副作用。本研究的目的是描述冰岛精神分裂症患者在接受氯氮平治疗期间便秘和肠梗阻的患病率,并评估可能导致便秘的药物的联合使用情况以及用于治疗便秘的泻药使用情况。
通过检索国家大学医院Landspitali在1998年1月1日至2014年11月21日研究期间的电子健康记录,我们确定了188例接受氯氮平治疗的患者。使用与肠梗阻相关的关键词在患者电子健康记录中进行电子检索,以确定便秘和肠梗阻病例。154例使用氯氮平至少一年的患者有详细的用药记录。
188例患者中有4例被诊断为肠梗阻并住院治疗。其中2例因肠梗阻需要永久性造口。在154例服用氯氮平的患者中,有24例(15.4%)开具了泻药。总共有40.9%的患者要么开具了泻药,要么病历中有便秘记录。在154例患者中,有28例(18.2%)除氯氮平外还服用了其他已知会导致便秘的药物。
便秘是氯氮平治疗期间的常见问题,可能发展为严重的肠梗阻,甚至可能致命。临床医生在氯氮平治疗期间需要监测便秘迹象,并通过生活方式建议和泻药治疗来应对。